Parkinson's Disease Biomarkers in Nerve Cells in the Gut

Description

Parkinson's disease affects all the nerve cells in the body, including the ones in the gut. The gut contains its own nervous system, the enteric nervous system, and can be thought of as a "second brain". This second brain can reflect what is going on in the actual brain. This study is being done to look for biomarkers, or early indicators of developing Parkinson's disease, in the microbiome and in the gut tissue taken during routine screening colonoscopy. People aged 45 and over who are due for their routine screening colonoscopy are eligible to participate.

Conditions

Parkinson Disease

Talk to us

Study Overview

On this page

Study Details

Study overview

Parkinson's disease affects all the nerve cells in the body, including the ones in the gut. The gut contains its own nervous system, the enteric nervous system, and can be thought of as a "second brain". This second brain can reflect what is going on in the actual brain. This study is being done to look for biomarkers, or early indicators of developing Parkinson's disease, in the microbiome and in the gut tissue taken during routine screening colonoscopy. People aged 45 and over who are due for their routine screening colonoscopy are eligible to participate.

Biochemical Characterization of Parkinson's Disease-related Proteins in the Enteric Nervous System as a Proxy for Pathological Changes in the Brain

Parkinson's Disease Biomarkers in Nerve Cells in the Gut

Condition
Parkinson Disease
Intervention / Treatment

-

Contacts and Locations

New York

Weill Cornell Medicine, New York, New York, United States, 10021

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age 45-75 years old
  • * Parkinson's Disease defined by the modified UK Parkinson's Disease Society Brain Bank criteria, at risk for the development of Parkinson's disease including REM sleep behavior disorder and/or at least one first degree relative with PD or related disorder, and diseases related to Parkinson's disease including the synucleinopathies Lewy Body Dementia and Multiple System Atrophy.
  • * Baseline Hoehn \& Yahr score 1-4
  • * No contraindications to undergoing screening colonoscopy
  • * Able to give informed consent for study participation
  • * Clinical features suggestive of a neurodegenerative diagnosis other than synucleinopathy.
  • * Diagnosis of primary mitochondrial disorder, epilepsy, stroke, multiple sclerosis or other neurodegenerative diseases such as Alzheimer's disease, Progressive Supranuclear Palsy (PSP), and Corticobasal syndrome.
  • * Significant concomitant medical disease limiting life expectancy to less than 24 months from study inclusion, or significant and serious concomitant medical disease that is poorly controlled
  • * Signs of active malignant disease or other clinically relevant abnormality on chest x-ray
  • * Active or untreated gastrointestinal disease
  • * Inability to temporarily stop anti-platelet agents or other anti-coagulants without significant risk
  • * Known substance abuse (recent history of abuse of alcohol or other drugs such as barbiturates, cannabinoids and amphetamines) within last 5 years
  • * Contraindication to colonoscopy or associated anesthesia
  • * Pregnancy
  • * In the opinion of the investigator, any other condition regarded as making subject unsuitable for the study

Ages Eligible for Study

45 Years to 75 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Weill Medical College of Cornell University,

Jacqueline Burre, PhD, PRINCIPAL_INVESTIGATOR, Weill Medical College of Cornell University

Virginia M Gao, MD PhD, PRINCIPAL_INVESTIGATOR, Weill Medical College of Cornell University

Study Record Dates

2025-06-01